close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

6.775 +0.055 (+0.82%)
Streaming Delayed Price Updated: 10:55 AM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Stockholder Alert: Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action Against ARDX
From Robbins LLP
Via GlobeNewswire
News headline image
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS
Via AB Newswire
News headline image
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
3 mid-caps under $20 that Wall Street loves
MarketBeat's Stock Screener tool helped identify these three mid-cap stocks - with very bullish Wall Street sentiment - that are currently under $20 per share 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
From Ardelyx, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today